Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study

OBJECTIVE: Describe the long-term outcomes of early-start (ES) and delayed-start (DS) glatiramer acetate 40 mg/mL treatment three times weekly (GA40) for up to seven years in the Glatiramer Acetate Low-frequency Administration (GALA) study in patients with relapsing multiple sclerosis (RMS). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Rieckmann, Peter, Zivadinov, Robert, Boyko, Alexey, Selmaj, Krzysztof, Alexander, Jessica K., Kadosh, Shaul, Rubinchick, Svetlana, Bernstein-Hanlon, Emily, Stark, Yafit, Ashtamker, Natalia, Davis, Mat D., Khan, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671685/
https://www.ncbi.nlm.nih.gov/pubmed/34925876
http://dx.doi.org/10.1177/20552173211061550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671685/
https://www.ncbi.nlm.nih.gov/pubmed/34925876
http://dx.doi.org/10.1177/20552173211061550

Ejemplares similares